Page 1591 - Hematology_ Basic Principles and Practice ( PDFDrive )

1418 Part VII Hematologic Malignancies

Lonial S, Weiss BM, Usmani SZ, et al: Daratumumab monotherapy in Raje N, Roodman GD: Advances in the biology and treatment of bone
patients with treatment-refractory multiple myeloma (SIRIUS): an open- disease in multiple myeloma. Clin Cancer Res 17:1278, 2011.
label, randomised, phase 2 trial. Lancet 387:1551–1560, 2016. Richardson PG, Hungria VT, Yoon SS, et al: Panobinostat plus bortezomib
Mateos MV, Hernandez MT, Giraldo P, et al: Lenalidomide plus dexa- and dexamethasone in previously treated multiple myeloma: outcomes by
methasone for high-risk smoldering multiple myeloma. N Engl J Med prior treatment. Blood 127:713–721, 2016.
369:438–447, 2013. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and
McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell dexamethasone combination therapy in patients with newly diagnosed
transplantation for multiple myeloma. N Engl J Med 366:1770–1781, multiple myeloma. Blood 116:679–686, 2010.
2012. Roussel M, Lauwers-Cances V, Robillard N, et al: Front-line transplantation
Moreau P, Masszi T, Grzasko N, et al: Oral ixazomib, lenalidomide, and program with lenalidomide, bortezomib, and dexamethasone combination
dexamethasone for multiple myeloma. N Engl J Med 374:1621–1634, as induction and consolidation followed by lenalidomide maintenance in
2016. patients with multiple myeloma: a phase II study by the Intergroupe
Morgan GJ, Child JA, Gregory WM, et al: Effects of zoledronic acid versus Francophone du Myélome. J Clin Oncol 32:2712–2717, 2014.
clodronic acid on skeletal morbidity in patients with newly diagnosed Stewart AK, Rajkumar SV, Dimopoulos MA, et al: Carfilzomib, lenalido-
multiple myeloma (MRC Myeloma IX): secondary outcomes from a mide, and dexamethasone for relapsed multiple myeloma. N Engl J Med
randomised controlled trial. Lancet Oncol 12:743, 2011. 372:142–152, 2015.
Munshi NC, Anderson KC: Minimal residual disease in multiple myeloma. Szalat R, Munshi NC: Genomic heterogeneity in multiple myeloma. Curr
J Clin Oncol 31:2523–2526, 2013. Opin Genet Dev 30:56–65, 2015.
Munshi NC, Anderson KC, Bergsagel PL, et al: Consensus recommendations Szalat R, Munshi NC: Next-generation sequencing informing therapeutic
for risk stratification in multiple myeloma: report of the International decisions and personalized approaches. Am Soc Clin Oncol Educ Book
Myeloma Workshop Consensus Panel 2. Blood 117:4696–4700, 2011. 35:e442, 2016.
Palumbo A, Avet-Loiseau H, Oliva S, et al: Revised international staging
system for multiple myeloma: a report from International Myeloma
Working Group. J Clin Oncol 33:2863–2869, 2015. REFERENCES
Palumbo A, Cavallo F, Gay F, et al: Autologous transplantation and main-
tenance therapy in multiple myeloma. N Engl J Med 371:895–905, For the complete list of references, log on to www.expertconsult.com.
2014.
Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment
for newly diagnosed multiple myeloma. N Engl J Med 366:1759–1769,
2012.